Passage Bio Inc (PASG)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.65-2.11%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PASG
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -43.6% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
PASG — private placement
Dated 2026-09-02
Entry into a Material Definitive Agreement. Amended and Restated Merger Agreement As previously disclosed, on June 24, 2026, Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”), Peregrine Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Company (“ Merger Sub ”), and Remix Therapeutics, Inc., a Delaware corporation (“ Remix ”), entered into an Agreement and Plan of Merger (the “ Original Merger Agreement ”), pursuant to which, among other matters and subject to…
Why it matters: If healthcare sector revenue growth speeds up, it may benefit Passage Bio. This could improve investor sentiment.
Supportive ifHealthcare sector revenue growth is speeding up again. It is moving toward 10% or more.
Worry ifHealthcare sector revenue growth continues to slow below 5%.
Why it matters: Updates on the clinical trial can impact future partnerships and funding. It shows the company's growth potential.
Watch forManagement shares good news about PBFT02 trial results or new partnerships.
Also watch forManagement reports setbacks or delays in the PBFT02 clinical trial.
Why it matters: The restructuring aims to cut costs significantly. Its success affects financial health.
Worry ifThe company finished the workforce reduction plan. It reached the goal of a 75% cut.
Less concerning ifThe restructuring fails to meet the targeted cost reductions or is delayed.
Why it matters: Extending the cash runway through 1Q 2027 is crucial for ongoing operations.
Supportive ifThe company shares news of a successful funding round or cost cuts to extend cash.
Worry ifThe company reports a cash runway that shortens or does not extend as planned.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $898 loss on $10,000 · 9.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,945 loss on $10,000 · 79.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Finishing the workforce cut is key to reducing costs. It shows management's commitment to improving finances.
Supportive ifManagement confirms the workforce reduction is complete by the end of Q3 2026.
Worry ifThe workforce reduction is delayed beyond Q3 2026.
Why it matters: Restructuring aims to cut costs and help finances. This will affect future operations.
Supportive ifThe workforce cut will finish by Q3 2026. This will lower operating costs.
Worry ifThe restructuring is delayed or does not achieve the targeted cost reductions.
Why it matters: The review's outcome could change the company's direction. It may also affect shareholder value.
Watch forThe company will announce a specific action, like a merger or partnership.
Also watch forThe review ends with no action taken. This shows there are no good options.
Why it matters: Keeping enough cash is important for running the business. It helps fund projects.
Worry ifManagement reports cash runway is extended through at least 1Q 2027.
Less concerning ifManagement says cash runway is getting shorter or cash burn is going up a lot.
Why it matters: The merger is crucial for Passage Bio's future. It will change ownership and operations significantly.
Supportive ifThe merger closes in Q4 2026 as planned, with no delays or issues.
Worry ifThe merger may be delayed or not happen. This is due to regulatory or shareholder issues.
Why it matters: FDA's guidance will shape the future of PBFT02's development. A randomized trial is a significant hurdle.
Worry ifFDA accepts the proposed design for a randomized controlled trial for PBFT02.
Less concerning ifThe FDA wants more studies. It may also reject the trial design for PBFT02.
Why it matters: Positive results could boost confidence in PBFT02 and the company's future. Negative results could hinder progress.
Watch forInterim data shows big improvements. This is in brain atrophy and plasma NfL levels for PBFT02.
Also watch forNew data shows no improvement in brain atrophy or plasma NfL levels for PBFT02.
Why it matters: The review could lead to significant changes in company direction. It may affect shareholder value.
Watch forThe company announces a new partnership or acquisition. This move adds value.
Also watch forThe strategic review leads to no action. It may also harm shareholder value.